At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- VERVE-201 (drug)
- How long the study runs
- Study runs about 38 months (dates as stated)
- About the drug or intervention
- VERVE-201 — drug: Intravenous (IV) infusion
- Patient visit burden
- Not specified by the sponsor
In plain English
This is an early-stage (Phase 1b) study testing a treatment called VERVE-201 in people with refractory hyperlipidemia. This means high levels of cholesterol or triglycerides (a type of fat in the blood) that have not responded well to treatment. The study is funded by Verve Therapeutics, Inc.
Who can take part
- Cholesterol levels that stay high despite treatment (refractory hypercholesterolemia)
- Triglyceride levels (blood fats) that stay high despite treatment (refractory hypertriglyceridemia)
Who may not be able to
- Liver disease now or in the past
- Current or recent treatment with a monoclonal antibody (a lab-made protein medicine) targeting ANGPTL3, or one given within a timeframe set by the study
- Laboratory test results that are unusual or concerning, as defined by the study plan
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team about visits, duration, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years to 70 Years
- Who
- All
- Number of participants
- 36
- Started
- 2024-10-30
- Last checked
- 2026-07
Plain English Summary
What is this study?
- • Testing a new treatment for hypercholesterolemia
- • Phase1 - 36 participants
- • VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia
Who can take part?
- • Ages 18 Years to 70 Years
- • Diagnosed with hypercholesterolemia
Where?
- • Liverpool - Clinical Study Center
- • London - Clinical Study Center
- • Manchester - Clinical Study Center 2
- • Manchester - Clinical Study Center
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 70 Years
- Who can join: All genders
What the study is looking for
- ✓Refractory hypercholesterolemia
- ✓Refractory hypertriglyceridemia
Who cannot take part
- ✗Active or history of chronic liver disease
- ✗Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
- ✗Clinically significant or abnormal laboratory values as defined by the protocol
See the full criteria
Where Is This Study? (4 UK sites)
Clinical Study Center
Liverpool, United Kingdom
Clinical Study Center
London, United Kingdom
Clinical Study Center 2
Manchester, United Kingdom
Clinical Study Center
Manchester, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT